EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intensification of rAAV Production Based on HEK293 Cell Transient Transfection

Ye Zhang iD, Emil Sundäng Peters, Olalekan Daramola, Trudy Ann Tucker, Johan Rockberg, Diane Hatton, Véronique Chotteau

Biotechnology Journal · 2025

DOI: 10.1002/biot.70020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Ye Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cell Technology Group (CETEG), Dept. of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, AdBIOPRO, VI…. Hauptthemen laut MEDLINE: Transfection, Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant adeno‐associated virus (rAAV) vectors are widely used in gene therapies, but the rapidly increasing global demand has created a significant challenge for rAAV manufacturing, where production capacity remains a critical bottleneck. To address this, strategies to enhance production yields are urgently needed. This study presents an innovative approach to rAAV production using high cell density (HCD) stirred tank perfusion culture. rAAV1 and rAAV9 vectors carrying GFP cargo were used as models, with triple‐plasmid transfection performed in suspension HEK293 cells at a high viable cell density of 50 million cells/mL in culture then maintained at ≥ 30 million cells/mL throughout production. Transfection and production parameters were first optimized in a 5 mL pseudo‐perfusion spin tube screening system at HCD. A proof‐of‐concept was then demonstrated by scaling up to a 200 mL stirred tank bioreactor (STR) in perfusion mode. This intensified process achieved rAAV9 production levels per cell comparable to those observed in reference shake flask cultures at 1 million cells/mL. By implementing transfection at very HCD in a perfusion‐based STR, this approach has the potential to significantly enhance rAAV volumetric production capacity, providing a promising solution to meet the growing demand for gene therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TransfectionDependovirusGenetic VectorsHumansHEK293 CellsBioreactorsGenetic TherapyGreen Fluorescent Proteins

Stichwörter der Autor:innen

PEIbioreactorhigh cell densityperfusionprocess intensificationrAAVrecombinant adeno‐associated viral vectorstriple plasmid transient transfection

Substanzen

Green Fluorescent Proteins

Autor:innen und Institutionen

  • Cell Technology Group (CETEG), Dept. of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health, AdBIOPRO, VINNOVA Competence Centre for Advanced Bioproduction by Continuous Proce…
  • Cell Culture and Fermentation Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Cell Culture and Fermentation Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Dept. Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.

ORCID-Profile: Ye Zhang

Zitieren

APA

Zhang, Y., Peters, E. S., Daramola, O., Tucker, T. A., Rockberg, J., Hatton, D., & Chotteau, V. (2025). Intensification of rAAV Production Based on HEK293 Cell Transient Transfection. Biotechnology Journal. https://doi.org/10.1002/biot.70020

Vancouver

Zhang Y, Peters ES, Daramola O, Tucker TA, Rockberg J, Hatton D, et al. Intensification of rAAV Production Based on HEK293 Cell Transient Transfection. Biotechnology Journal. 2025. doi:10.1002/biot.70020

BibTeX
@article{Zhang2025,
  author = {Zhang, Ye and Peters, Emil Sundäng and Daramola, Olalekan and Tucker, Trudy Ann and Rockberg, Johan and Hatton, Diane and Chotteau, Véronique},
  title = {Intensification of rAAV Production Based on HEK293 Cell Transient Transfection},
  journal = {Biotechnology Journal},
  year = {2025},
  doi = {10.1002/biot.70020}
}
Kostenlos starten →